Compare Illinois Tool Works Inc. (ITW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Pfizer Inc — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2.1× Illinois Tool Works Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Pfizer Inc for 158 Days on average.
| ITW | PFE | |
|---|---|---|
Market Cap | $74.38B | $159.59B |
Volume | 1,125,477 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $299.60 | $29.02 |
52-Week Low | $241.07 | $23.67 |
Typical Hold Time | 67 Days | 158 Days |
Enterprise Value | $83.23B | $211.09B |
Dividend Yield | 2.63% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.
Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
